NCT06590051|Unknown
AMG 335 Expanded Access Program for IgG4-Related Disease
1 other identifier
AMG335 Expanded Access Program
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredSep 2024
Brief Summary
Expanded access requests for AMG 335 may be considered for adult patients with a confirmed diagnosis of IgG4-related disease. To request access, use Responsible Party contact information provided in this record.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 6, 2024
Completed13 days until next milestone
First Posted
Study publicly available on registry
September 19, 2024
CompletedLast Updated
September 19, 2024
Status Verified
September 1, 2024
First QC Date
September 6, 2024
Last Update Submit
September 6, 2024
Interventions
UPLIZNADRUG
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Amgenlead
Study Officials
- STUDY DIRECTOR
MD
Amgen
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 6, 2024
First Posted
September 19, 2024
Last Updated
September 19, 2024
Record last verified: 2024-09